John L. LaMattina, serving as a director at Ligand Pharmaceuticals Inc. (NASDAQ:LGND), executed a substantial divestment of company equity on June 10, 2026. The insider transaction resulted in the sale of common stock valued at approximately $1,151,774. This disposal activity was structured through multiple direct market sales, involving a total of 4,591 shares. The execution of these sales occurred across four distinct blocks, with share prices varying between $247.2237 and $251.6158 per share.
The specific breakdown of the transaction reveals that 257 shares were sold at prices ranging from $246.6300 to $247.6100. In a subsequent block, 232 shares were disposed of at prices between $247.9400 and $248.3350. The third block involved the sale of 697 shares, with execution prices falling within the range of $249.3400 to $250.2700. The largest portion of the transaction consisted of 3,405 shares sold at prices ranging from $250.9100 to $251.8950. Following the completion of these transactions, Mr. LaMattina's direct holding in Ligand Pharmaceuticals common stock stands at 26,969 shares.
This insider sale occurs while Ligand Pharmaceuticals shares are trading near their 52-week high of $258.56. The stock has delivered a notable 122% return over the past year, reflecting significant price appreciation. Despite this strong performance, analysis indicates that the stock currently appears overvalued relative to its Fair Value. The company carries a market capitalization of $5.11 billion and trades at a P/E ratio of 32.1.
In conjunction with the insider transaction, Ligand Pharmaceuticals reported its first-quarter 2026 earnings results, which did not meet analysts' expectations. The company announced an adjusted earnings per share (EPS) of $1.63, falling short of the anticipated $1.84. Revenue also missed projections, coming in at $51.72 million compared to the expected $59.07 million. This resulted in a revenue surprise of 12.44% below expectations.
Additionally, Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty Corporation. The amendment involves adding XOMA Royalty Holdings Corporation as a party to the agreement. Under the revised terms, Flex Merger Sub, Inc., a wholly owned subsidiary of Ligand, will merge with and into HoldCo, a newly formed subsidiary of XOMA Royalty. Following the merger, HoldCo will continue as a wholly owned subsidiary of Ligand Pharmaceuticals.